SUBSCRIBE
Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2008, Vol. 6 ›› Issue (2): 134-138.doi: 10.3736/jcim20080206

• Original Clinical Research • Previous Articles     Next Articles

Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: A randomized controlled trial

Zhu-yi Zhang1, Shi-qing Yu2(), Li-yun Miao2, Xiao-ying Huang2, Xiao-ping Zhang2, Yu-ping Zhu2, Xiao-hong Xia2, Dan-qi Li2   

  1. 1. Department of Respiratory Medicine, Dongguan Kuanghua Hospital, Dongguan, Guangdong Province 523080, China
    2. Department of Respiratory Medicine, Nantong Rich Hospital, Nantong, Jiangsu Province 226010, China
  • Received:2007-06-10 Online:2008-02-20 Published:2008-02-15
  • Contact: YU Shi-qing E-mail:ahyshq@163.com

RichHTML

5

PDF (PC)

69

Like

Objective:To our knowledge, there has been no clinical report of artesunate in the treatment of lung cancer. This study was designed to compare the efficacy and toxicity of artesunate combined with NP (a chemotherapy regimen of vinorelbine and cisplatin) and NP alone in the treatment of advanced non-small cell lung cancer (NSCLC).

Methods:One hundred and twenty cases of advanced NSCLC were randomly divided into simple chemotherapy group (control group, n=60) and combined artesunare with chemotherapy group (trial group, n=60). Patients in the control group were treated with NP regimen, including vinorelbine (25 mg/m 2, once-a-day intravenous injection, at the 1st and 8th day) and cisplatin (25 mg/m 2, once-a day intravenous drip, at the 2nd to 4th day). Patients in the trial group were treated with the basal therapy NP (in the same method and doses as control group) and artesunate (120 mg, once-a-day intravenous injection, from the 1st day to 8th day, for 8 days). At least two 21-day-cycles of treatment were performed. The short-term survival rate, disease controlled rate (DCR), time to progression (TTP), mean survival time (MST) and 1-year survival rate were analyzed as the primary end points, and the toxicity and safety were estimated.

Results:There were no significant differences in the short-term survival rate, MST and 1-year survival rate between the trial group and the control group, which were 45.1% and 34.5%, 44 weeks and 45 weeks, 45.1% and 32.7%, respectively (P>0.05). The DCR of the trial group (88.2%) was significantly higher than that of the control group (72.7%) (P<0.05), and the trial group's TTP (24 weeks) was significantly longer than that of the control group (20 weeks) (P<0.05). No significant difference was found in toxicity between the two groups, such as myelosuppression and digestion reaction (P>0.05).

Conclusion:Artesunate can be used in the treatment of NSCLC. Artesunate combined with NP can elevate the short-term survival rate and prolong the TTP of patients with advanced NSCLC without extra side effects.

Key words: antineoplastic combined chemotherapy protocols, antineoplastic drugs (TCD), non-small-cell lung carcinoma, randomized controlled trial

CLC Number: 

  • R734.2

Figure 1

Survival time curves of the patients in artesunate group and control groupLog-rank test result: survival processes of two groups are identical (x2=0.83, P=0.3615)."

Figure 2

Time to progression curves of the patients in artesunate group and control groupLog-rank test result: processes of disease progression of two groups are different (x2=6.77, P=0.0093), and the progression process of the artesunate group is slow."

[1] Liu JL, Zheng ZY , Yu RX. Mechanisms of antitumor activities of artemisinin and its derivatives. Zhong Yao Xin Yao Yu Lin Chuang Yao Li. 2006; 17(2):155-157. Chinese.
doi: 10.3321/j.issn:1003-9783.2006.02.025
刘俊玲, 郑智茵, 虞荣喜 . 青蒿素及其衍生物的抗肿瘤机制探讨.中药新药与临床药理. 2006; 17(2):155-157.
doi: 10.3321/j.issn:1003-9783.2006.02.025
[2] Efferth T, Sauerbrey A, Olbrich A , et al. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol. 2003; 64(2):382-394.
doi: 10.1124/mol.64.2.382
[3] Sadava D, Phillips T, Lin C , et al. Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett. 2002; 179(2) : 151-156.
doi: 10.1016/S0304-3835(02)00005-8 pmid: 11888669
[4] Efferth T, Volm M . Glutathion-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate. In Vivo. 2005; 19(1):225-232.
[5] Lu CY, Chen XY , Tang BH. A Study in effect of artemisinin and its derivatives on reversion of multi-drug resistance of tumors. Zhongguo Zhong Yi Yao Xin Xi Za Zhi. 2006; 13(4):12-14. Chinese with abstract in English.
doi: 10.3969/j.issn.1005-5304.2006.04.006
吕翠岩, 陈信义, 唐炳华 . 青蒿素及其衍生物逆转肿瘤耐药作用初探.中国中医药信息杂志. 2006; 13(4):12-14.
doi: 10.3969/j.issn.1005-5304.2006.04.006
[6] Balint GA . Artemisinin and its derivatives: an important new class of antimalarial agents. Pharmacol Ther. 2001; 90(2-3):261-265.
doi: 10.1016/S0163-7258(01)00140-1 pmid: 11578659
[7] Therasse P, Arbuck SG, Eisenhauer EA , et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-216.
doi: 10.1093/jnci/92.3.205 pmid: 11174117
[8] Miller AB, Hoogstraten B, Staquet M , et al. Reporting results of cancer treatment. Cancer. 1981; 47(1) : 207-14.
doi: 10.1002/(ISSN)1097-0142
[9] Miao LY, Zhang ZY. Reversal effect of artesunate on the multidrug-resistance of human leukemia K562/A02 cells. Dong Nan Da Xue Xue Bao ( Yi Xue Ban ). 2006; 25(6):445-447. Chinese with abstract in English.
苗立云, 张祖贻 . 青蒿琥醋逆转K562/A02细胞对阿霉素耐药性机理的研究. 东南大学学报(医学版). 2006; 25(6):445-447.
[10] Miao LY , Zhang ZY. The possible mechanism of artesunate s selective cytotoxicity toward human lung adenocarcinoma cells. Xian Dai Yi Xue. 2006; 34(1):15-17. Chinese with abstract in English.
doi: 10.3969/j.issn.1671-7562.2006.01.005
苗立云, 张祖贻 . 青蒿琥醋选择性抗肺腺癌细胞的作用及其机制. 现代医学. 2006; 34(1):15-17.
doi: 10.3969/j.issn.1671-7562.2006.01.005
[11] Chen WQ, Qi HW , Wu CG. Effect of dihydroartemisi- nin on the proliferation of human lung adenocarcinoma cell line A549 in vitro. Zhongguo Xin Yi Yao. 2004; 3(5):9-10. Chinese with abstract in English.
陈卫强, 戚好文, 吴昌归 . 双氢青蒿素对人肺腺癌 A549细胞的体外抑制作用研究.中国新医药. 2004; 3(5):9-10.
[12] Chen WQ, Qi HW, Wu CG , et al. Inhibition of growth on the human lung adenocarcinoma cell line A549 and A549/CDDP in vitro by dihydroartemisinin in combination with cisplatin. Xian Dai Zhong Liu Yi Xue. 2006; 14(3):284-286. Chinese with abstract in English.
陈卫强, 戚好文, 吴昌归 , 等. 双氢青蒿素逆转人肺腺癌细胞多药耐药作用研究.现代肿瘤医学. 2006; 14(3):284-286.
[13] Di Leo A, Bleiberg H, Buyse M . Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol. 2003; 21(10):2045-2047.
[14] Singh NP, Lai H . Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. LifeSci. 2001; 70(1):49-56.
doi: 10.1016/S0024-3205(01)01372-8 pmid: 11764006
[15] Efferth T, Benakis A, Romero MR , et al. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med. 2004; 37(7):998-1009.
doi: 10.1016/j.freeradbiomed.2004.06.023 pmid: 15336316
[1] Sherman Gu, Arthur Yin Fan. Controversial conclusions from two randomized controlled trials for acupuncture's effects on polycystic ovary syndrome or in vitro fertilization support. Journal of Integrative Medicine, 2020, 18(2): 89-91.
[2] Gerli E.G. Herr, Fábio Goulart da Silva, Francisco José Cidral-Filho, Fabricia Petronilho, Lucinéia Gainski Danielski, Mariana Pereira de Souza Goldim, Afonso Shiguemi Inoue Salgado, Franciane Bobinski, Daniel Fernandes Martins, Eliane R. Winkelmann. Effects of the use of bioceramic wraps in patients with lower limb venous ulcers: A randomized double-blind placebo-controlled trial. Journal of Integrative Medicine, 2020, 18(1): 27-.
[3] Xin-yu Yue, Zhuo-qi Feng, Xi-yi Yu, Jia-min Hu, Xiao-Jing He, Shi Shu. Fire-needle acupuncture for upper limb spastic paralysis after stroke: Study protocol for a randomized controlled trial. Journal of Integrative Medicine, 2019, 17(3): 167-172.
[4] Ya-ru Huangfu, Wei Peng, Bao-jun Guo, Zhi-fu Shen, Li Li, Shi-wei, Liu, Hui Zheng, You-ping Hu. Effects of acupuncture in treating insomnia due to spleen-stomach disharmony syndrome and its influence on intestinal microbiome: Study protocol for a randomized controlled trial. Journal of Integrative Medicine, 2019, 17(3): 161-167.
[5] Pádraic J.Dunne, Julie Lynch, Lucia Prihodova, Caoimhe O'Leary, Atiyeh Ghoreyshi, Sharee A. Basdeo, Donal J.Cox, Rachel Breen, Ali Sheikhi, Áine Carroll, Cathal Walsh, Geraldine McMahon, Barry White. Burnout in the emergency department: Randomized controlled trial of an attention-based training program. Journal of Integrative Medicine, 2019, 17(3): 173-180.
[6] J.M. Oliver-Baxter, H.S. Whitford, D.A. Turnbull, M.J. Bond. Effects of vitamin supplementation on inflammatory markers and psychological wellbeing among distressed women: A randomized controlled trial. Journal of Integrative Medicine, 2018, 16(5): 322-328.
[7] Parunkul Tungsukruthai, Preecha Nootim, Wiwan Worakunphanich, Nareerat Tabtong. Efficacy and safety of herbal steam bath in allergic rhinitis: A randomized controlled trial. Journal of Integrative Medicine, 2018, 16(1): 39-44.
[8] Zahra Hajmohammadi, Mojtaba Heydari, Majid Nimrouzi, Pouya Faridi, Mohammad Javad Zibaeenezhad, Gholamhossein Ranjbar Omrani, Mesbah Shams . Rhus coriaria L. increases serum apolipoprotein-A1 and high-density lipoprotein cholesterol levels: A double-blind placebo-controlled randomized clinical trial. Journal of Integrative Medicine, 2018, 16(1): 45-50.
[9] Laura Belland, Laura Rivera-Reyes, Ula Hwang. Using music to reduce anxiety among older adults in the emergency department: A randomized pilot study. Journal of Integrative Medicine, 2017, 15(6): 450-455.
[10] Hilal Yuksel, Yasemin Cayir, Zahide Kosan, Kenan Tastan. Effectiveness of breathing exercises during the second stage of labor on labor pain and duration: A randomized controlled trial. Journal of Integrative Medicine, 2017, 15(6): 456-461.
[11] Yoshiharu Motoo, Takashi Hakamatsuka, Nobuo Kawahara, Ichiro Arai, Kiichiro Tsutani. Standards of Reporting Kampo Products (STORK) in research articles. Journal of Integrative Medicine, 2017, 15(3): 182-185.
[12] Maria T.Chao, AlexandraChang, SanjayReddy, James D.Harrison, JosephAcquah, MiriaToveg, TrilceSantana, Frederick M.Hecht. Adjunctive acupuncture for pain and symptom management in the inpatient setting: Protocol for a pilot hybrid effectiveness-implementation study. Journal of Integrative Medicine, 2016, 14(3): 228-238.
[13] Nouran A. Aleyeidi, Khaled S. Aseri, Shadia M. Matbouli, Albaraa A. Sulaiamani, Sumayyah A. Kobeisy. Effects of wet-cupping on blood pressure in hypertensive patients: A randomized controlled trial. Journal of Integrative Medicine, 2015, 13(6): 391-399.
[14] Maria Sousa Cláudia, Coimbra Daniela, Machado Jorge, J. Greten Henry. Effects of self-administered exercises based on Tuina techniques on musculoskeletal disorders of professional orchestra musicians: A randomized controlled trial. Journal of Integrative Medicine, 2015, 13(5): 314-318.
[15] Marco Gemma, Elisa Nicelli, Luigi Gioia, Elena Moizo, Luigi Beretta, Maria Rosa Calvi. Acupuncture accelerates recovery after general anesthesia: A prospective randomized controlled trial. Journal of Integrative Medicine, 2015, 13(2): 99-104.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] Wei-xiong Liang. Problems-solving strategies in clinical treatment guideline for traditional Chinese medicine and integrative medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 1-4
[2] Yi-ting He, Qing-lin Zha, Jian-ping Yu, Yong Tan, Cheng Lu, Ai-ping Lv. Principal factor analysis of symptoms of rheumatoid arthritis and their correlations with efficacy of traditional Chinese medicine and Western medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 32-36
[3] Jun Cai, Hua Wang, Sheng Zhou, Bin Wu, Hua-rong Song, Zheng-rong Xuan. Effect of Sijunzi Decoction and enteral nutrition on T-cell subsets and nutritional status in patients with gastric cancer after operation: A randomized controlled trial. Journal of Chinese Integrative Medicine, 2008, 6(1): 37-40
[4] Dong Yang, Yong-ping Du, Qing Shen, Wei Chen, Yan Yu, Guang-lei Chen. Expression of alpha-smooth muscle actin in renal tubulointerstitium in patients with kidney collateral stasis. Journal of Chinese Integrative Medicine, 2008, 6(1): 41-44
[5] A-gao Zhou, Yong Zhang, Gang Kui, De-Yun Kong, Hai-liang Ge, Qiu-hua Ren, Jia-rong Dong, Sheng Hong, Xu-ming Mao, Yin Wang, Hui-zheng Zhang, Shu-jun Wang. Influence of traditional Chinese compound recipes with different efficacy on body weight, tumor weight and immune function in H22 cancer-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 77-82
[6] Xi Lin, Jian-ping Liu. Tai chi for treating rheumatoid arthritis. Journal of Chinese Integrative Medicine, 2008, 6(1): 82
[7] Guo-hong Yuan, Xiao-jing Pang, He-chao Ma. Synergic effects of Danggui Buxue Decoction in reducing toxicity of cytoxan in tumor-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 83-88
[8] Li Zhou, Hong-xing Zhang, Ling-guang Liu, Wen-jun Wan. Effect of electro-acupuncture at Fenglong (GV 16) on nitric oxide and endothelin in rats with hyperlipidemia. Journal of Chinese Integrative Medicine, 2008, 6(1): 89-92
[9] Ning-qun Wang, Liang-duo Jiang, Zong-xing Li. Research progress in asthma-related quality of life. Journal of Chinese Integrative Medicine, 2008, 6(1): 93-97
[10] Daniel Weber, Janelle M Wheat, Geoffrey M Currie. Inflammation and cancer: Tumor initiation, progression and metastasis,and Chinese botanical medicines. Journal of Chinese Integrative Medicine, 2010, 8(11): 1006-1013
Journal of Integrative Medicine, ISSN: 2095-4964 CN 31-2083/R
Copyright © Journal of Integrative Medicine
Powered by Beijing Magtech Co. Ltd
沪公网安备31010602003416号      沪ICP备18017633号-3